The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

The Lunaphore COMET™ platform is a fully automated liquid handler and microscope imaging scanner capable of performing sequential, multiplex, immunofluorescent staining and imaging samples adherent to ...

Acrivon has developed AP3 Interactome, a proprietary, computational analytics platform driven by machine learning for integrated comprehensive analyses across all large, in-house AP3 phosphoproteomic ...

“The immune response is really important for cancer control, but it was neglected for decades,” says Anna Wilkins, urological cancer consultant at The Royal Marsden and clinician scientist at ...

Acrivon Therapeutics (ACRV) announced the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device designation, BDD, for the ...

The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...

HAMBURG, Germany, December 12, 2024--(BUSINESS WIRE)--ZEISS partners with Mindpeak, a pioneer in AI-powered pathology solutions, to develop an integrated Multiplex Immunofluorescence (mIF ...

Members of Nagel's group then determined the capacities of the various DNA repair pathways in the different brain regions using a technique called "fluorescence multiplex host cell reactivation ...